These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 22265844

  • 1. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K.
    Adv Drug Deliv Rev; 2012 May 01; 64(6):480-95. PubMed ID: 22265844
    [Abstract] [Full Text] [Related]

  • 2. Theory and practice of supersaturatable formulations for poorly soluble drugs.
    Kawakami K.
    Ther Deliv; 2015 Mar 01; 6(3):339-52. PubMed ID: 25853309
    [Abstract] [Full Text] [Related]

  • 3. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs.
    Cerpnjak K, Zvonar A, Gašperlin M, Vrečer F.
    Acta Pharm; 2013 Dec 01; 63(4):427-45. PubMed ID: 24451070
    [Abstract] [Full Text] [Related]

  • 4. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability.
    Kohli K, Chopra S, Dhar D, Arora S, Khar RK.
    Drug Discov Today; 2010 Nov 01; 15(21-22):958-65. PubMed ID: 20727418
    [Abstract] [Full Text] [Related]

  • 5. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T, Sarmento B, Costa P.
    Drug Discov Today; 2007 Dec 01; 12(23-24):1068-75. PubMed ID: 18061887
    [Abstract] [Full Text] [Related]

  • 6. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P, Pillay V, Ndesendo VM, du Toit LC, Choonara YE.
    Biopharm Drug Dispos; 2011 May 01; 32(4):185-209. PubMed ID: 21480294
    [Abstract] [Full Text] [Related]

  • 7. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y, Porter W, Merdan T, Li LC.
    Expert Opin Drug Deliv; 2009 Dec 01; 6(12):1261-82. PubMed ID: 19941409
    [Abstract] [Full Text] [Related]

  • 8. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N, de Matas M, Gavan PT, York P.
    Adv Drug Deliv Rev; 2007 Jul 30; 59(7):617-30. PubMed ID: 17597252
    [Abstract] [Full Text] [Related]

  • 9. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs.
    Müllertz A, Ogbonna A, Ren S, Rades T.
    J Pharm Pharmacol; 2010 Nov 30; 62(11):1622-36. PubMed ID: 21039546
    [Abstract] [Full Text] [Related]

  • 10. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H.
    Eur J Pharm Sci; 2007 Aug 30; 31(5):249-61. PubMed ID: 17616376
    [Abstract] [Full Text] [Related]

  • 11. Lipid nanoparticles for the delivery of poorly water-soluble drugs.
    Bunjes H.
    J Pharm Pharmacol; 2010 Nov 30; 62(11):1637-45. PubMed ID: 21039547
    [Abstract] [Full Text] [Related]

  • 12. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S.
    Int J Pharm; 2011 Nov 25; 420(1):1-10. PubMed ID: 21884771
    [Abstract] [Full Text] [Related]

  • 13. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET, Cadé D, Benameur H.
    Adv Drug Deliv Rev; 2008 Mar 17; 60(6):747-56. PubMed ID: 18096270
    [Abstract] [Full Text] [Related]

  • 14. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM, Griffin BT.
    Adv Drug Deliv Rev; 2008 Mar 17; 60(6):617-24. PubMed ID: 18155800
    [Abstract] [Full Text] [Related]

  • 15. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I.
    Expert Opin Drug Deliv; 2005 May 17; 2(3):419-33. PubMed ID: 16296764
    [Abstract] [Full Text] [Related]

  • 16. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
    van Hoogevest P, Liu X, Fahr A.
    Expert Opin Drug Deliv; 2011 Nov 17; 8(11):1481-500. PubMed ID: 21895540
    [Abstract] [Full Text] [Related]

  • 17. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R, Dand N.
    J Control Release; 2017 Feb 28; 248():71-95. PubMed ID: 28088572
    [Abstract] [Full Text] [Related]

  • 18. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs.
    Vo CL, Park C, Lee BJ.
    Eur J Pharm Biopharm; 2013 Nov 28; 85(3 Pt B):799-813. PubMed ID: 24056053
    [Abstract] [Full Text] [Related]

  • 19. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.
    Cherniakov I, Domb AJ, Hoffman A.
    Expert Opin Drug Deliv; 2015 Jul 28; 12(7):1121-33. PubMed ID: 25556987
    [Abstract] [Full Text] [Related]

  • 20. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A, Hoffman A.
    J Control Release; 2008 Jul 02; 129(1):1-10. PubMed ID: 18499294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.